Get the Stockscreener App
15.00
5.71%
0.81
Eloxx Pharmaceuticals Inc stock is traded at $15.00, with a volume of 38,840.
It is up +5.71% in the last 24 hours and down -18.61% over the past month.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
See More
Previous Close:
$14.19
Open:
$14.06
24h Volume:
38,840
Relative Volume:
0.90
Market Cap:
$51.54M
Revenue:
-
Net Income/Loss:
$-17.92M
P/E Ratio:
-2.1423
EPS:
-7.0019
Net Cash Flow:
$-17.78M
1W Performance:
-0.46%
1M Performance:
-18.61%
6M Performance:
-75.18%
1Y Performance:
-68.68%
1-Day Range:
$14.06
$16.48
1-Week Range:
$13.79
$17.32
52-Week Range:
$8.20
$23.40
Eloxx Pharmaceuticals Inc Stock (ELOX) Company Profile
Name
Eloxx Pharmaceuticals Inc
Sector
Industry
Phone
781-577-5300
Address
P.O. BOX 274, ARLINGTON
Compare ELOX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELOX
Eloxx Pharmaceuticals Inc
|
15.00 | 61.99M | 0 | -17.92M | -17.78M | -7.0019 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eloxx Pharmaceuticals Inc Stock (ELOX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Initiated | B. Riley Securities | Buy |
| Jun-11-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-06-19 | Initiated | Janney | Buy |
| Dec-24-18 | Initiated | H.C. Wainwright | Neutral |
| Jul-03-18 | Initiated | Citigroup | Buy |
View All
Eloxx Pharmaceuticals Inc Stock (ELOX) Latest News
Lucid Capital Initiates Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Announces Target Price $38 - Moomoo
Eloxx Pharmaceuticals initiated with a Buy at Lucid Capital - TipRanks
Lucid Capital Markets initiates Eloxx Pharma stock with buy rating - Investing.com
Lucid Capital Markets initiates Eloxx Pharma stock with buy rating By Investing.com - Investing.com India
Eloxx Pharmaceuticals, Inc. Common Stock (NASDAQ: ELOX) Stock Price, News & Analysis - Kalkine
Eloxx Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
Equity in earnings of Eloxx Pharmaceuticals, Inc. – FWB:J36 - TradingView
Eloxx Pharmaceuticals, Inc. Statistics – FWB:J36 - TradingView
J36 Forecast — Price Target — Prediction for 2027 - TradingView
ETFs Investing in Eloxx Pharmaceuticals, Inc. Stocks - TradingView
Eloxx Pharmaceuticals (ELOX) stake hits 9.99% for Samsara affiliate - Stock Titan
Nantahala Capital discloses 9.91% Eloxx Pharmaceuticals (ELOX) ownership in Schedule 13G - Stock Titan
LifeSci Capital Maintains Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Eloxx Pharmaceuticals Q2 net loss widens on higher expenses - TradingView
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Form 8K Eloxx Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Nigeria
Eloxx Pharmaceuticals reports Q2 2026 net loss $4.5M, $62.0M cash after $66.0M offering - TradingView
8-K: Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Updatemoomoo - Moomoo
Eloxx Pharmaceuticals, Inc. 2Q 2026: Net loss $4.5M, EPS $(0.66) — 10-Q Summary - TradingView
ELOX: Raised $58.3M in public offering, advancing exaluren trials amid rising operating losses - TradingView
Eloxx Pharmaceuticals (NASDAQ: ELOX) boosts cash with $58.3M equity raise - stocktitan.net
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Eloxx Pharmaceuticals Ord Shs (ELOX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Biotech Stocks At 52-Week HighsANGO, ANIK, ELOX, YARW, PLSE - RTTNews
Eloxx Pharmaceuticals (ELOXD) Financials 2026Income Statement and Balance Sheet - MarketBeat
abrdn Inc. (ELOX) discloses 400,000-share, 9.91% holding in Eloxx - Stock Titan
ELOX|Eloxx Pharmaceuticals Ord Shs|Price:11.940|Chg%:-0.060 - TradingKey
Eloxx Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ELOX - TradingView
ELOX Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBIT forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
Price to earnings forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
ELOX stock holds on report context and clinical milestones - Ad-hoc-news.de
Eloxx Pharmaceuticals (ELOX) Q4 2025 earnings summary - Quartr
Eloxx Pharmaceuticals (ELOX) Registration filing Summary - Quartr
Eloxx Pharmaceuticals (ELOX) Q1 2026 earnings summary - Quartr
LifeSci Capital Initiates Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Announces Target Price $40 - Moomoo
Guggenheim Initiates Eloxx Pharmaceuticals at Buy With $43 Price Target - marketscreener.com
Eloxx Pharmaceuticals initiated with a Buy at Guggenheim - TipRanks
Guggenheim initiates Eloxx Pharma stock with buy on kidney data By Investing.com - Investing.com Canada
Guggenheim Initiates Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Announces Target Price $43 - Moomoo
ELOX Price Today: Eloxx Pharmaceuticals, Inc. Stock Price, Quote & Chart - mexc.co
Eloxx Pharmaceuticals2026 Funding Rounds & List of Investors - Tracxn
Price to book forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
ELOX stock trades on Nasdaq as small-cap biotech focuses on cystic fibrosis therapy - Ad-hoc-news.de
ELOX|Eloxx Pharmaceuticals Ord Shs|Price:12.270|Chg%:+1.320 - TradingKey
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq - AOL.com
Price to sales forward of Eloxx Pharmaceuticals, Inc. – BOATS:ELOX - TradingView
Enterprise value to EBITDA forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
Eloxx Pharma (ELOX) Stock Analysis Report | Financials & Insights - Benzinga España
Eloxx’s EXACT Study Puts Exaluren in Focus for Rare Kidney Disease Investors - TipRanks
ELOXEloxx Pharmaceuticals Inc Latest SEC Filings - Finviz
Eloxx Pharmaceuticals Inc Stock (ELOX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):